Actinium Pharmaceuticals Appoints Matt David, M.D. as Chief Financial Officer
Actinium Pharmaceuticals Names Matt David as CFO and Principal Financial Officer, Bringing Over Two Decades of Experience in Biopharmaceutical Leadership and Capital Markets
Actinium Pharmaceuticals, Inc., a company focused on developing targeted radiotherapies, has appointed Matt David, M.D., as Chief Financial Officer (CFO) and principal financial officer. He will oversee the company’s finance, accounting, capital markets and investor relations functions.
David brings more than two decades of experience spanning biopharmaceutical leadership, healthcare investment banking and equity research. He joins Actinium from CorMedix Inc., where he most recently served as Executive Vice President and Chief Business Officer. He initially joined CorMedix in 2020 as Executive Vice President and CFO.
During his tenure at CorMedix, the company received US Food and Drug Administration (FDA) approval for DefenCath in 2023 and launched the product commercially in 2024. In 2025, CorMedix acquired a commercial anti-infectives company, expanding its operations into a diversified, commercial-stage specialty pharmaceutical business.
Before joining CorMedix, David served as Head of Strategy at Ovid Therapeutics Inc. Earlier in his career, he spent more than a decade in healthcare investment banking at BofA Merrill Lynch, Thomas Weisel Partners and Piper Jaffray, advising biopharmaceutical companies on financing and strategic transactions. He also worked as an equity research associate at Lehman Brothers, covering the pharmaceutical sector.
Actinium Chairman and CEO Sandesh Seth highlighted David’s experience guiding a company through FDA approval, commercial launch and a major acquisition. He also noted David’s combination of medical knowledge, capital markets expertise and strategic leadership as the company advances its radiotherapy pipeline.
David said he was joining Actinium at a significant time for radiopharmaceutical development. He highlighted the company’s ATNM-400 programme, the clinically validated Actimab-A programme and its expertise in actinium-225 as important opportunities for future growth.
David earned his medical degree from NYU School of Medicine and completed a surgery residency at Beth Israel Hospital. He also holds an undergraduate degree in Chemistry from Dartmouth College.